Investigational Drug Information for Aceclidine
✉ Email this page to a colleague
What is the development status for investigational drug Aceclidine?
Aceclidine is an investigational drug.
There have been 9 clinical trials for Aceclidine.
The most recent clinical trial was a Phase 2 trial, which was initiated on February 21st 2023.
The most common disease conditions in clinical trials are Presbyopia, Eye Diseases, and Refractive Errors. The leading clinical trial sponsors are ORA, Inc., LENZ Therapeutics, Inc, and Presbyopia Therapies, LLC.
There are ninety-seven US patents protecting this investigational drug and zero international patents.
Summary for Aceclidine
| US Patents | 97 |
| International Patents | 1,998 |
| US Patent Applications | 619 |
| WIPO Patent Applications | 282 |
| Japanese Patent Applications | 86 |
| Clinical Trial Progress | Phase 2 (2023-02-21) |
| Vendors | 49 |
Recent Clinical Trials for Aceclidine
| Title | Sponsor | Phase |
|---|---|---|
| Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia | LENZ Therapeutics, Inc | Phase 3 |
| Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia | Ji Xing Pharmaceuticals (Shanghai) Co., Ltd. | Phase 3 |
| Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia | ORA, Inc. | Phase 1 |
Clinical Trial Summary for Aceclidine
Top disease conditions for Aceclidine
Top clinical trial sponsors for Aceclidine
US Patents for Aceclidine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Aceclidine | ⤷ Sign Up | Micro-RNA, autoantibody and protein markers for diagnosis of neuronal injury | Banyan Biomarkers, Inc. (Alachua, FL) The United States of America, as Represented by the Secretary of the Army (Washington, DC) | ⤷ Sign Up |
| Aceclidine | ⤷ Sign Up | Substituted pyridobenzodiazepinone-derivatives and use thereof | Bayer Pharma Aktiengesellschaft (Berlin, DE) | ⤷ Sign Up |
| Aceclidine | ⤷ Sign Up | WT1 peptide cancer vaccine composition for transdermal administration | NITTO DENKO CORPORATION (Osaka, JP) OSAKA UNIVERSITY (Osaka, JP) | ⤷ Sign Up |
| Aceclidine | ⤷ Sign Up | Vaccine composition | NITTO DENKO CORPORATION (Osaka, JP) | ⤷ Sign Up |
| Aceclidine | ⤷ Sign Up | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Aceclidine
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Aceclidine | China | CN106029628 | 2034-04-16 | ⤷ Sign Up |
| Aceclidine | European Patent Office | EP3133058 | 2034-04-16 | ⤷ Sign Up |
| Aceclidine | Japan | JP6273539 | 2034-04-16 | ⤷ Sign Up |
| Aceclidine | Japan | JPWO2015159611 | 2034-04-16 | ⤷ Sign Up |
| Aceclidine | South Korea | KR102388452 | 2034-04-16 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
